Ecological photodynamic therapy: New trend to disrupt the intricate networks within tumor ecosystem

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 1, 2013, Pages 86-99

  Rumie Vittar, N Belén ^a   Lamberti, María Julia ^a   Pansa, María Florencia ^a   Vera, Renzo E ^a   Rodriguez, M Exequiel ^a   Cogno, I Sol ^a   Milla Sanabria, Laura N ^a   Rivarola, Viviana A ^a  

^a DEPARTAMENTO DE QUÍMICA   (Argentina)

Author keywords

Angiogenesis; Ecosystem; Hypoxia; Photodynamic therapy; Stroma; Tumor microenvironment

Indexed keywords

CELL ADHESION MOLECULE; FIBROBLAST GROWTH FACTOR 2; GALECTIN 1; GAMMA INTERFERON; HEAT SHOCK PROTEIN 47; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OXYGEN; PHOTOSENSITIZING AGENT; PLATELET DERIVED GROWTH FACTOR; PROTEIN LYSINE 6 OXIDASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VERTEPORFIN; VIMENTIN;

ANGIOGENESIS; BASEMENT MEMBRANE; CANCER INHIBITION; CANCER RESEARCH; CANCER RESISTANCE; CELL ACTIVATION; CELL HYPOXIA; CELL INTERACTION; CELL SURVIVAL; CELLULAR IMMUNITY; CELLULAR STRESS RESPONSE; CLINICAL EFFECTIVENESS; CORNEA NEOVASCULARIZATION; ECOLOGICAL PHOTODYNAMIC THERAPY; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; MACROPHAGE; OXIDATIVE STRESS; PHENOTYPE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

ANIMALS; HUMANS; NEOPLASMS; PHOTOCHEMOTHERAPY; TUMOR MICROENVIRONMENT;

EID: 84870208173     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.10.004     Document Type: Review

References (141)

1. Miller G.T.J., Spoolman S.E. Essentials of ecology 2007, Brooks/Cole. 5th ed.
2. Ungefroren H., Sebens S., Seidl D., Lehnert H., Hass R. Interaction of tumor cells with the microenvironment. Cell Commun. Signal. 2011, 9:18.
3. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
4. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
5. Kareva I. What can ecology teach us about cancer?. Transl. Oncol. 2011, 4:266-270.
6. Brahimi-Horn M., Pouyssegur J. Harnessing the hypoxia- inducible factor in cancer and ischemic disease. Biochem. Pharmacol. 2007, 73:450-457.
7. Mazure N., Brahimi-Horn M., Berta M., Benizri E., Bilton R., Dayan F., Ginouvès A., Berra E., Pouysségur J. HIF-1: master and commander of the hypoxic world A pharmacological approach to its regulation by siRNAs. Biochem. Pharmacol. 2004, 68:971-980.
8. Krishnamachary B., Berg-dixon S., Kelly B., Agani F., Feldser D., Ferreira G., Iyer N., Larusch J., Pak B., Taghavi P., Semenza G.L. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1 regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1 1. Cancer Res. 2003, 1138-1143.
9. Semenza G. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
10. Manalo D., Rowan A., Lavoie T., Natarajan L., Kelly B., Ye S., Garcia J., Semenza G. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005, 105:659-669.
11. Schofield C., Ratcliffe P. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004, 5:343-354.
12. Semenza G. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
13. Lu X., Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res. 2010, 16:5928-5935.
14. Dayan F., Mazure N.M., Brahimi-Horn M.C., Pouysségur J. A dialogue between the hypoxia-inducible factor and the tumor microenvironment. Cancer Microenviron. 2008, 1:53-68.
15. Witz I.P. The tumor microenvironment: the making of a paradigm. Cancer Microenviron. 2009, 2:9-17.
16. Herbert S.P., Stainier D.Y.R. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat. Rev. Mol. Cell Biol. 2011, 12:551-564.
17. Hanahan D., Weinberg R. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
18. Ruoslahti E. Specialization of tumour vasculature. Nat. Rev. Cancer 2002, 2:83-90.
19. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
20. Xiong Y., Sun H., Zhang W., Zhu X., Zhuang P., Zhang J., Wang L., Wu W., Qin L., Tang Z. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin. Cancer Res. 2009, 15:4838-4846.
21. Bussolati B., Grange C., Bruno S., Buttiglieri S., Deregibus M., Tei L., Aime S., Camussi G. Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. Exp. Cell Res. 2006, 312:913-924.
22. Hida K., Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res. 2005, 65:2507-2510.
23. Hida K., Hida Y., Amin D., Flint A., Panigrahy D., Morton C., Klagsbrun M. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 2004, 64:8249-8255.
24. Akino T., Hida K., Hida Y., Tsuchiya K., Freedman D., Muraki C., Ohga N., Matsuda K., Akiyama K., Harabayashi T., Shinohara N., Nonomura K., Klagsbrun M., Shindoh M. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am. J. Pathol. 2009, 175:2657-2667.
25. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
26. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 2009, 86:1065-1073.
27. Gordon S., Taylor P. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
28. Dace D.S., Khan A.A., Kelly J., Apte R.S. Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development. PLoS One 2008, 3:e3381.
29. Murdoch C., Muthana M., Coffelt S., Lewis C. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
30. Lewis C., Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am. J. Pathol. 2005, 167:627-635.
31. Kalluri R., Zeisberg M. Fibroblast in cancer. Nat. Rev. Cancer 2006, 6:392-401.
32. Räsänen K., Vaheri A. Activation of fibroblasts in cancer stroma. Exp. Cell Res. 2010, 316:2713-2722.
33. Orimo A., Weinberg R.A. Stromal fibroblast in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 515:1597-1601.
34. Allen M., Jones J.L. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J. Pathol. 2011, 223:162-176.
35. Gullberg D., Reed R.K. Tumor-stroma interactions: focus on fibroblasts. Mouse as a Model Organism 2011, 117-130. Springer Netherlands, Dordrecht. C. Brakebusch, T. Pihlajaniemi (Eds.).
36. Giaccia A.J., Schipani E. Role of carcinoma-associated fibroblasts and hypoxia in tumor progression. Diverse Effects of Hypoxia on Tumor Progression 2010, 31-45.
37. Fidler I.J. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat. Rev. 2003, 3:1-6.
38. Huijbers I.J., Iravani M., Popov S., Robertson D., Al-Sarraj S., Jones C., Isacke C.M. A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion. PLoS One 2010, 5:9808.
39. Levental K.R., Yu H., Kass L., Lakins J.N., Erler J.T., Fong S.F.T., Csiszar K., Giaccia A., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2010, 139:891-906.
40. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
41. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 2003, 3:422-433.
42. Sottile J. Regulation of angiogenesis by extracellular matrix. Biochim. Biophys. Acta 2004, 1654:13-22.
43. Avraamides C.J., Garmy-Susini B., Varner J.A. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 2008, 8:604-617.
44. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29:15-18.
45. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 2011, 17:1359-1370.
46. Liao D., Johnson R. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007, 26:281-290.
47. Milla L., Yslas E., Cabral A., Durantini E., Romanini S., Rivarola V., Bertuzzi M. Pharmacokinetic, toxicological and phototherapeutic studies of phthalocyanine ZnPcCF3. Biomed. Pharmacother. 2009, 63:209-215.
48. Alvarez M., Prucca C., Milanesio M., Durantini E., Rivarola V. Photodynamic activity of a new sensitizer derived from porphyrin-C60 dyad and its biological consequences in a human carcinoma cell line. Int. J. Biochem. Cell Biol. 2006, 38:2092-2101.
49. Milanesio M., Alvarez M., Silber J., Rivarola V., Durantini E. Photodynamic activity of monocationic and non-charged methoxyphenylporphyrin derivatives in homogeneous and biological media. Photochem. Photobiol. Sci. 2003, 2:926-933.
50. Alvarez M., Príncipe F., Milanesio M., Durantini E., Rivarola V. Photodynamic damages induced by a monocationic porphyrin derivative in a human carcinoma cell line. Int. J. Biochem. Cell Biol. 2005, 37:2504-2512.
51. Milanesio M., Alvarez M., Rivarola V., Silber J., Durantini E. Porphyrin-fullerene C60 dyads with high ability to form photoinduced charge-separated state as novel sensitizers for photodynamic therapy. Photochem. Photobiol. 2005, 81:891-897.
52. Yslas E., Rivarola V., Durantini E. Synthesis and photodynamic activity of zinc(II) phthalocyanine derivatives bearing methoxy and trifluoromethylbenzyloxy substituents in homogeneous and biological media. Bioorg. Med. Chem. 2005, 13:39-46.
53. Yslas E., Prucca C., Romanini S., Durantini E., Bertuzzi M., Rivarola V. Biodistribution and phototherapeutic properties of Zinc (II) 2,9,16,23-tetrakis (methoxy) phthalocyanine in vivo. Photodiagnosis Photodyn. Ther. 2009, 6:62-70.
54. Vittar N., Awruch J., Azizuddin K., Rivarola V. Caspase-independent apoptosis, in human MCF-7c3 breast cancer cells, following photodynamic therapy, with a novel water-soluble phthalocyanine. Int. J. Biochem. Cell Biol. 2010, 42:1123-1131.
55. Alvarez M., Morán F., Yslas E., Vittar N., Bertuzzi M., Durantini E., Rivarola V. Pharmacokinetic and tumour-photosensitizing properties of methoxyphenyl porphyrin derivative. Biomed. Pharmacother. 2003, 57:163-168.
56. Milla L., Cogno I., Rodríguez M., Sanz-Rodríguez F., Zamarrón A., Gilaberte Y., Carrasco E., Rivarola V., Juarranz A. Isolation and characterization of squamous carcinoma cells resistant to photodynamic therapy. J. Cell. Biochem. 2011, 112:2266-2278.
57. Núñez Montoya S., Comini L., Rumie Vittar B., Fernández I., Rivarola V., Cabrera J. Phototoxic effects of Heterophyllaea pustulata (Rubiaceae). Toxicon 2008, 51:1409-1415.
58. Yslas E., Ibarra L., Peralta D., Barbero C., Rivarola V., Bertuzzi M. Polyaniline nanofibers: acute toxicity and teratogenic effect on Rhinella arenarum embryos. Chemosphere 2012, 87:1374-1380.
59. Vittar N., Prucca C., Strassert C., Awruch J., Rivarola V. Cellular inactivation and antitumor efficacy of a new zinc phthalocyanine with potential use in photodynamic therapy. Int. J. Biochem. Cell Biol. 2008, 40:2192-2205.
60. Cogno I., Vittar N., Lamberti M., Rivarola V. Optimization of photodynamic therapy response by survivin gene knockdown in human metastatic breast cancer T47D cells. J. Photochem. Photobiol. B 2011, 104:434-443.
61. Yslas E., Durantini E., Rivarola V. Zinc-(II) 2,9,16,23-tetrakis (methoxy) phthalocyanine: potential photosensitizer for use in photodynamic therapy in vitro. Bioorg. Med. Chem. 2007, 15:4651-4660.
62. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., Hahn S.M., Hamblin M.R., Juzeniene A., Kessel D. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 2011, 61:250-281.
63. Dolmans D., Kadambi A., Hill J., Flores K., Gerber J., Walker J., Borel Rinkes I., Jain R., Fukumura D. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Res. 2002, 62:4289-4294.
64. Bhuvaneswari R., Gan Y.Y., Lucky S.S., Chin W.W.L., Ali S.M., Soo K.C., Olivo M. Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy. Mol. Cancer 2008, 7:56.
65. Weiss A., van der Bergh H., Griffioen A.W., Nowak-Sliwinska P. Angiogenesis inhibition for the improvement of photodynamic therapy: the revival of a promising idea. Biochim. Biophys. Acta 2012, 1826:53-70.
66. Ran S., Downes A., Thorpe P. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002, 62:6132-6140.
67. Takeuchi Y., Kurohane K., Ichikawa K., Yonezawa S., Nango M., Oku N. Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer. Cancer 2003, 97:2027-2034.
68. Takeuchi Y., Kurohane K., Ichikawa K., Yonezawa S., Ori H., Koishi T., Nango M., Oku N. Polycation liposome enhances the endocytic uptake of photosensitizer into cells in the presence of serum. Bioconjug. Chem. 2003, 14:790-796.
69. Palumbo A., Hauler F., Dziunycz P., Schwager K., Soltermann A., Pretto F., Alonso C., Hofbauer G., Boyle R., Neri D. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br. J. Cancer 2011, 104:1106-1115.
70. Fabbrini M., Trachsel E., Soldani P., Bindi S., Alessi P., Bracci L., Kosmehl H., Zardi L., Neri D., Neri P. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int. J. Cancer 2006, 118:1805-1813.
71. Allen C., Sharman W., La Madeleine C., Weber J., Langlois R., Ouellet R., van Lier J. Photodynamic therapy: tumor targeting with adenoviral proteins. Photochem. Photobiol. 1999, 70:512-523.
72. Chen J., Wang H., Li C., Han K., Zhang X., Zhuo R. Construction of surfactant-like tetra-tail amphiphilic peptide with RGD ligand for encapsulation of porphyrin for photodynamic therapy. Biomaterials 2011, 32:1678-1684.
73. Castellani A., Pace G., Concioli M. Photodynamic effect of haematoporphyrin on blood microcirculation. J. Pathol. Bacteriol. 1963, 86:99-102.
74. Chen B., Pogue B., Hoopes P., Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit. Rev. Eukaryot. Gene Expr. 2006, 16:279-305.
75. Olivo M., Chin W. Perylenequinones in photodynamic therapy: cellular versus vascular response. J. Environ. Pathol. Toxicol. Oncol. 2006, 25:223-237.
76. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res. 2001, 21:4271-4277.
77. Tammela T., Saaristo A., Holopainen T., Ylä-Herttuala S., Andersson L., Virolainen S., Immonen I., Alitalo K. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci. Transl. Med. 2011, 3. (69ra11).
78. Schmidt-Erfurth U., Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv. Ophthalmol. 2000, 45:195-214.
79. Kurohane K., Tominaga A., Sato K., North J., Namba Y., Oku N. Photodynamic therapy targeted to tumor-induced angiogenic vessels. Cancer Lett. 2001, 167:49-56.
80. Shimizu K., Oku N. Cancer anti-angiogenic therapy. Biol. Pharm. Bull. 2004, 27:599-605.
81. Peng Q., Nesland J. Effects of photodynamic therapy on tumor stroma. Ultrastruct. Pathol. 2004, 28:333-340.
82. Nowak-Sliwinska P., Weiss A., van Beijnum J., Wong T., Ballini J., Lovisa B., van den Bergh H., Griffioen A. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J. Cell. Mol. Med. 2011, 16:1553-1562.
83. Nowak-Sliwinska P., Wagnières G., van den Bergh H., Griffioen A. Angiostasis-induced vascular normalization can improve photodynamic therapy. Cell. Mol. Life Sci. 2010, 67:1559-1560.
84. Ferrario A., Tiehl K.F.V., Rucker N., Schwarz M.A., Gill P.S., Gomer C.J. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 2000, 4066-4069.
85. Gomer C.J., Ferrario A., Luna M., Rucker N., Wong S. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg. Med. 2006, 38:516-521.
86. Bhuvaneswari R., Gan Y.Y., Soo K.C., Olivo M. The effect of photodynamic therapy on tumor angiogenesis. Cell. Mol. Life Sci. 2009, 66:2275-2283.
87. Ji Z., Yang G., Shahzidi S., Tkacz-Stachowska K., Suo Z., Nesland J.M., Peng Q. Induction of hypoxia-inducible factor-1alpha overexpression by cobalt chloride enhances cellular resistance to photodynamic therapy. Cancer Lett. 2006, 244:182-189.
88. Koukourakis M.I., Giatromanolaki A., Skarlatos J., Corti L., Blandamura S., Piazza M., Gatter K.C., Harris A.L. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 2001, 61:1830-1832.
89. Mitra S., Cassar S.E., Niles D.J., Puskas J.A., Frelinger J.G., Foster T.H. Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha. Mol. Cancer Ther. 2006, 5:3268-3274.
90. Galanis A., Pappa A., Giannakakis A., Lanitis E., Dangaj D., Sandaltzopoulos R. Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett. 2008, 266:12-20.
91. Evans C.L., Abu-Yousif A.O., Park Y.J., Klein O.J., Celli J.P., Rizvi I., Zheng X., Hasan T. Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDT. PLoS One 2011, 6:e23434.
92. Lee K., Roth R., LaPres J. Hypoxia, drug therapy and toxicity. Pharmacol. Ther. 2007, 113:229-246.
93. Magagnin M., Koritzinsky M., Wouters B. Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies. Drug Resist. Updat. 2006, 9:185-197.
94. Singh G., Alqawi O., Espiritu M. Metronomic PDT and cell death pathways. Methods Mol. Biol. 2010, 635:65-78.
95. Pienta K.J., McGregor N., Axelrod R., Axelrod D.E. Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl. Oncol. 2008, 1:158-164.
96. Hsu A., Veeravagu A., Cai W., Hou L., Tse V., Chen X. Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment. Recent Pat. Anticancer Drug Discov. 2007, 2:143-158.
97. Francavilla C., Maddaluno L., Cavallaro U. The functional role of cell adhesion molecules in tumor angiogenesis. Semin. Cancer Biol. 2009, 19:298-309.
98. Volanti C., Gloire G., Vanderplasschen A., Jacobs N., Habraken Y., Piette J. Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy. Oncogene 2004, 23:8649-8658.
99. Udartseva O., Andreeva E., Buravkova L., Knizhnik A., Vozovikov I. Low-fluence photodynamic treatment modifies functional properties of vascular cell wall. Bull. Exp. Biol. Med. Aug 2011, 151(4):521-525. (151 (2011) 521-525).
100. Deininger M., Weinschenk T., Morgalla M., Meyermann R., Schluesener H. Release of regulators of angiogenesis following Hypocrellin-A and -B photodynamic therapy of human brain tumor cells. Biochem. Biophys. Res. Commun. 2002, 298.
101. Sawamiphak S., Seidel S., Essmann C., Wilkinson G., Pitulescu M., Acker T., Acker-Palmer A. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2012, 465:487-491.
102. Wu X., Liu N. The role of Ang/Tie signaling in lymphangiogenesis. Lymphology 2010, 43:59-72.
103. Triesscheijn M., Ruevekamp M., Aalders M., Baas P., Stewart F.A. Comparative sensitivity of microvascular endothelial cells, fibroblasts and tumor cells after in vitro photodynamic therapy with meso-tetra-hydroxyphenyl-chlorin. Photochem. Photobiol. 2004, 80:236-241.
104. Zenzen V., Zankl H. In vitro evaluation of the cytotoxic and mutagenic potential of the 5-aminolevulinic acid hexylester-mediated photodynamic therapy. Mutat. Res. 2004, 561:91-100.
105. Pittet O., Petermann D., Michod D., Krueger T., Cheng C., Ris H.B., Widmann C. Effect of the TAT-RasGAP(317-326) peptide on apoptosis of human malignant mesothelioma cells and fibroblasts exposed to meso-tetra-hydroxyphenyl-chlorin and light. J. Photochem. Photobiol. B 2007, 88:29-35.
106. Maduray K., Karsten A., Odhav B., Nyokong T. In vitro toxicity testing of zinc tetrasulfophthalocyanines in fibroblast and keratinocyte cells for the treatment of melanoma cancer by photodynamic therapy. J. Photochem. Photobiol. B 2011, 103:98-104.
107. Glidden M.D., Massodi I., Rizvi I., Celli J.P., Hasan T. Probing tumor-stroma interactions and response to photodynamic therapy in a 3D pancreatic cancer-fibroblast co-culture model. Proc. SPIE 2012, 8210:821006.
108. Shackley D., Haylett A., Whitehurst C., Betts C., O'Flynn O., Clarke N., Moore J. Comparison of the cellular molecular stress responses after treatments used in bladder cancer. BJU Int. 2002, 90:924-932.
109. Verrico A., Haylett A., Moore J. In vivo expression of the collagen-related heat shock protein HSP47, following hyperthermia or photodynamic therapy. Lasers Surg. Med. 2001, 16:192-198.
110. Verrico A., Moore J. Expression of the collagen-related heat shock protein HSP47 in fibroblasts treated with hyperthermia or photodynamic therapy. Br. J. Cancer 1997, 76:719-724.
111. Mala J.G., Rose C. Interactions of heat shock protein 47 with collagen and the stress response: an unconventional chaperone model?. Life Sci. 2010, 87:579-586.
112. Uehara M., Inokuchi T., Tobita T., Ohba S., Asahina I. Expression of heat shock protein 47 in the fibrous tissue adjacent to mouse tumour subjected to photodynamic therapy. Oral Oncol. 2007, 43:804-810.
113. Karrer S., Bosserhoff A.K., Weiderer P., Landthaler M., Szeimies R.-M. Influence of 5-aminolevulinic acid and red light on collagen metabolism of human dermal fibroblasts. J. Invest. Dermatol. 2003, 120:325-331.
114. Takahashi H., Komatsu S., Ibe M., Ishida-Yamamoto A., Nakajima S., Sakata I., Iizuka H. ATX-S10(Na)-PDT shows more potent effect on collagen metabolism of human normal and scleroderma dermal fibroblasts than ALA-PDT. Arch. Dermatol. Res. 2006, 298:257-263.
115. Karrer S., Bosserhoff A., Weiderer P., Landthaler M., Szeimies R. Keratinocyte-derived cytokines after photodynamic therapy and their paracrine induction of matrix metalloproteinases in fibroblasts. Br. J. Dermatol. 2004, 151:776-783.
116. Taylor M., Lee Y., Schiemann W. Role of TGF-β and the tumor microenvironment during mammary tumorigenesis. Gene Expr. 2011, 15:117-132.
117. Byun J., Lee G., Choi H., Myung K., Choi Y. The expressions of TGF-β(1) and IL-10 in cultured fibroblasts after ALA-IPL photodynamic treatment. Ann. Dermatol. 2011, 23:19-22.
118. Davis G., Senger D. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 2005, 97:1093-1107.
119. Pazos M.D.C., Nader H.B. Effect of photodynamic therapy on the extracellular matrix and associated components. Braz. J. Med. Biol. Res. 2007, 40:1025-1035.
120. Maas A.L., Carter S.L., Wileyto E.P., Miller J., Yuan M., Yu G., Durham A.C., Busch T.M. Tumor vascular microenvironment determines responsiveness to photodynamic therapy. Cancer Res. 2012, 72:2079-2088.
121. Overhaus M., Heckenkamp J., Kossodo S., Leszczynski D., Lamuraglia G.M. Photodynamic therapy generates a matrix barrier to invasive vascular cell migration. Circ. Res. 2000, 86:334-340.
122. Therapy P., Waterman P.R., Overhaus M., Heckenkamp J., Nigri G.R., Fungaloi P.F.C., Landis M.E., Kossodo S.C., Lamuraglia G.M. Mechanisms of reduced human vascular cell migration after. Photochemistry 2002, 75:46-50.
123. Levental K., Yu H., Kass L., Lakins J., Egeblad M., Erler J., Fong S., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D., Weaver V. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
124. Schultz G., Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen. 2009, 17:153-162.
125. LaMuraglia G.M., Adili F., Karp S.J., Statius van Eps R.G., Watkins M.T. Photodynamic therapy inactivates extracellular matrix-basic fibroblast growth factor: insights to its effect on the vascular wall. J. Vasc. Surg. 1997, 26:294-301.
126. Freeman B., Crapo J. Biology of disease: free radicals and tissue injury. Lab. Invest. 1982, 47:412-426.
127. Heckenkamp J., Aleksic M., Gawenda M., Breuer S., Brabender J., Mahdavi A., Aydin F., Brunkwall J.S. Modulation of human adventitial fibroblast function by photodynamic therapy of collagen matrix. Eur. J. Vasc. Endovasc. Surg. 2004, 28:651-659.
128. Adili F., Statius van Eps R.G., Karp S.J., Watkins M.T., LaMuraglia G.M. Differential modulation of vascular endothelial and smooth muscle cell function by photodynamic therapy of extracellular matrix: novel insights into radical-mediated prevention of intimal hyperplasia. J. Vasc. Surg. 1996, 23:698-705.
129. Adili F., Scholz T., Hille M., Heckenkamp J., Barth S., Engert A., Schmitz-Rixen T. Photodynamic therapy mediated induction of accelerated re-endothelialisation following injury to the arterial wall: implications for the prevention of postinterventional restenosis. Eur. J. Vasc. Endovasc. Surg. 2002, 24:166-175.
130. Skivka L., Gorbik G., Fedorchuk O., Pozur V. Tumor-Associated Macrophages in the Prospect of Development of Targeted Anticancer Therapy. Cytol. Genet. 2009, 43:283-292.
131. Hamblin M., Miller J., Ortel B. Scavenger-receptor targeted photodynamic therapy. Photochem. Photobiol. 2000, 72:533-540.
132. Demidova T., Hamblin M. Macrophage-targeted photodynamic therapy. Int. J. Immunopathol. Pharmacol. 2004, 17:117-126.
133. Liu Q., Hamblin M. Macrophage-targeted photodynamic therapy: scavenger receptor expression and activation state. Int. J. Immunopathol. Pharmacol. 2005, 18:391-402.
134. Korbelik M., Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 1999, 137:91-98.
135. Postiglione I., Chiaviello A., Palumbo G. Enhancing photodynamyc therapy efficacy by combination therapy: dated, current and oncoming strategies. Cancers 2011, 3:2597-2629.
136. Evans S., Matthews W., Perry R., Fraker D., Norton J., Pass H. Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J. Natl. Cancer Inst. 1990, 8234-9:34-39.
137. Yamamoto N., Homma S., Sery T., Donoso L., Hoober J. Photodynamic immunopotentiation: in vitro activation of macrophages by treatment of mouse peritoneal cells with haematoporphyrin derivative and light. Eur. J. Cancer 1991, 27:467-471.
138. Yamamoto N., Hoober J., Yamamoto S. Tumoricidal capacities of macrophages photodynamically activated with hematoporphyrin derivative. Photochem. Photobiol. 1992, 56:245-250.
139. Coutier S., Bezdetnaya L., Marchal S., Melnikova V., Belitchenko I., Merlin J.L., Guillemin F. Foscan (mTHPC) photosensitized macrophage activation: enhancement of phagocytosis, nitric oxide release and tumour necrosis factor-alpha-mediated cytolytic activity. Br. J. Cancer 1999, 81:37-42.
140. Nowis D., Stoklosa T., Legat M., Issat T., Jakobisiak M., Golab J. The influence of photodynamic therapy on the immune response. Photodiagnosis Photodyn. Ther. 2005, 2:283-298.
141. M. Korbelik, W. Zhang, D. Separovic, Monitoring ceramide and sphingosine-1-phosphate levels in cancer cells andmacrophages fromtumours treated by photo-dynamic therapy, Photochem. Photobiol. Sci. (in press).